Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379773 | 0.93 | TSHR (0.61) | TSHRELANECETPIDO1AGXT | |
| SCHEMBL20123381 | 0.91 | TSHR (0.59) | TSHRELANECETPIDO1AGXT | |
| SCHEMBL79996 | 0.91 | TSHR (0.63) | TSHRELANECETPIDO1AGXT | |
| SCHEMBL743706 | 0.89 | TSHR (0.57) | TSHRELANECETP | |
| SCHEMBL2301938 | 0.89 | TSHR (0.57) | TSHRELANECETPIDO1AGXT | |
| SCHEMBL218693 | 0.89 | TSHR (0.57) | TSHRELANECETPIDO1AGXT | |
| SCHEMBL2365443 | 0.89 | TSHR (0.57) | TSHRELANECETPIDO1SRC | |
| SCHEMBL2980165 | 0.89 | TSHR (0.57) | TSHRELANECETP | |
| SCHEMBL12239114 | 0.89 | TSHR (0.62) | TSHRELANECETPSRCPDPK1 | |
| SCHEMBL3705923 | 0.88 | TSHR (0.55) | TSHRELANECETPIDO1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1052 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119114040-B | Preparation method and application of bionic phospholipid membrane monolithic column for screening and separating antimicrobial peptides | 佛山大学 | 2025-02-14 | — | — | CN | claimed |
| US-12220423-B2 | Compounds, derivatives, and analogs for cancer | HYGIA PHARMACEUTICALS, LLC (US) | 2025-02-11 | — | — | US | claimed |
| CN-119039098-A | Method for synthesizing styrene and derivatives thereof | 珠海固瑞泰复合材料有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-116589503-B | Iron-phosphorus complex, composite catalyst, syndiotactic 1, 2-polybutadiene, modified rare earth butadiene rubber and preparation method and application thereof | 浙江传化合成材料股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117887355-A | Paraffin emulsion waterproof agent | 黑龙江省木材科学研究所 | 2024-04-16 | — | — | CN | claimed |
| CN-117723696-A | Genetic metabolic disease screening method based on liquid chromatography-tandem mass spectrometry | 湖南中医药大学 | 2024-03-19 | — | — | CN | claimed |
| CN-114381156-B | Metal oxide dispersion composition, method for producing same, film composition containing same, optical film, and optical element | 凯斯科技股份有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-117186145-A | Preparation method of glyceraldehyde-3-phosphoric acid | 长沙晨辰医药科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116589503-A | Iron-phosphorus complex, composite catalyst, syndiotactic 1, 2-polybutadiene, modified rare earth butadiene rubber and preparation method and application thereof | 浙江传化合成材料有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-114716763-B | Aging-resistant conductive polypropylene functional material and preparation method thereof | 华润化学材料科技股份有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-1049177-C | Curable compositions | CIBA GEIGY AG (CH) | 2000-02-09 | — | — | CN | claimed |
| EP-0918364-A1 | Phosphate additives for non-aqueous electrolyte in alkali metal electrochemical cells | WILSON GREATBATCH LTD. (US) | 1999-05-26 | — | — | EP | claimed |
| US-5846456-A | Method of making gradient index optical element | NATIONAL SCIENCE COUNCIL (TW) | 1998-12-08 | — | — | US | claimed |
| US-5459248-A | Process of preparing etoposide phosphate and etoposide | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-17 | — | — | US | claimed |
| EP-0652226-A1 | Process of preparing etoposide phosphate and etoposide | Bristol-Myers Squibb Company (US) | 1995-05-10 | — | — | EP | claimed |
| US-5272035-A | Photosensitive lithographic printing plate having treated aluminum support with diazonium light-sensitive layer containing polyurethane resin and phosphorous additive | FUJI PHOTO FILM CO., LTD. (JP) | 1993-12-21 | — | — | US | claimed |
| US-4416877-A | Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds | SYMPHAR S.A. (CH) | 1983-11-22 | — | — | US | claimed |
| US-4151050-A | Process for producing sulfones | KERNFORSCHUNGSANLAGE JULICH GESELLSCHAFT (DE) | 1979-04-24 | — | — | US | claimed |
| US-4122258-A | Process for producing desacetoxycephalosporin derivatives by heating a penicillin-1-oxide in presence of an organic sulfide | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-10-24 | — | — | US | claimed |
| US-3953539-A | PHOSPHORUS COMPOUNDS | TEIJIN LTD. (JA) | 1976-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220423-B2 | Compounds, derivatives, and analogs for cancer | KRAS, PIK3CA, PIK3CD | TSHR 3046/4885ELANE 3671/4885CETP 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.